CN112352955A - Low-GI (glycemic index) total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on ketogenesis principle and application of low-GI total-nutrient meal replacement powder - Google Patents

Low-GI (glycemic index) total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on ketogenesis principle and application of low-GI total-nutrient meal replacement powder Download PDF

Info

Publication number
CN112352955A
CN112352955A CN202011254933.5A CN202011254933A CN112352955A CN 112352955 A CN112352955 A CN 112352955A CN 202011254933 A CN202011254933 A CN 202011254933A CN 112352955 A CN112352955 A CN 112352955A
Authority
CN
China
Prior art keywords
parts
vitamin
oil
meal replacement
replacement powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011254933.5A
Other languages
Chinese (zh)
Inventor
张洁
张�浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinshan Hospital of Fudan University
Original Assignee
Jinshan Hospital of Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinshan Hospital of Fudan University filed Critical Jinshan Hospital of Fudan University
Priority to CN202011254933.5A priority Critical patent/CN112352955A/en
Publication of CN112352955A publication Critical patent/CN112352955A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
    • A23L19/115—Konjak; Konntaku
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The invention relates to a low-GI total nutrient meal replacement powder for intervening polycystic ovarian syndrome based on a ketogenesis principle and application thereof, wherein the meal replacement powder consists of the following raw materials: raw coconut oil, conjugated linoleic acid glyceride, linseed oil, olive oil, fish oil, high oleic acid sunflower seed oil, soybean oil, concentrated lactalbumin, soybean protein isolate, hydrolyzed fish collagen, casein, rice protein, quinoa flour, chia seed, konjac powder, inulin, fructo-oligosaccharide, L-carnitine, glutamine, enzyme, compound vitamin and compound mineral substance. The formula has the advantages that: the energy supply ratio of the three nutrients is as follows: fat 70-75%, carbohydrate 3-5%, protein 20-27%. By utilizing the characteristic that MCT (medium-chain fatty acid) can not store fat and can rapidly supply energy to human bodies, the insulin resistance is reduced, the glycolipid metabolic disorder is improved, and the purpose of losing weight is achieved. Provides a scientific and convenient ketogenic diet alternative scheme, and is convenient for implementation and popularization in the crowd.

Description

Low-GI (glycemic index) total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on ketogenesis principle and application of low-GI total-nutrient meal replacement powder
Technical Field
The invention relates to the technical field of formula Food (FSMP) for special medical application, in particular to low-GI total nutrient meal replacement powder for intervening polycystic ovarian syndrome based on a ketogenic principle and application thereof.
Background
Polycystic ovarian syndrome (PCOS) is an endocrine disturbance syndrome in which reproductive dysfunction and abnormal carbohydrate metabolism coexist, is characterized by persistent anovulation, hyperandrogenemia and ovarian polycystic change, not only affects the reproductive function of a patient, but also increases the risk of endometrial cancer, type ii diabetes, cardiovascular diseases and the like. Affecting 5-20% of women of childbearing age, is one of the most common causes of infertility and metabolic disorders, the causes and mechanisms of the diseases are not clear, and no effective radical treatment method is available.
The research significance of the invention is as follows:
the incidence of PCOS increases year by year, with the 'second birth' policy opened in China, a large number of women have fertility requirements, the PCOS seriously influences the natural fertility success rate, the life quality of the women of the right age is reduced, the fertility requirements of the pregnant women of the right age are reduced, the couple relationship is worsened, and even the family is broken. In addition, obesity, hairy, acne frequently on the face, skin dark thorn skin and the like influence the needs of women for beauty. The further development of the disease can lead patients to have secondary type 2 diabetes, hypertension, cardiovascular diseases and the like, and the life of women is seriously influenced. Therefore, effective measures for treating PCOS are urgently needed to ensure female health and maintain family and social stability.
Epidemiological investigations have shown that the incidence of overweight or obesity in PCOS patients exceeds 40%, and that Insulin Resistance (IR) is present in 95% of overweight/obese PCOS patients. Patients with overweight/obese PCOS have defective hypothalamic-pituitary-ovarian axis regulation and decreased endometrial receptivity, are more prone to ovulation failure, increased miscarriage rates, decreased responsiveness to pregnancy-aid therapies, increased treatment costs, decreased pregnancy success rates, and increased risk of pregnancy complications.
Therefore, the primary treatment principle and direction for patients with PCOS is lifestyle-based weight loss. Clinical tests prove that: obese polycystic patients lose 10-15% of their weight and some recover spontaneous menses, and 40-50% of polycystic patients with improved insulin resistance can recover regular menses without drug intervention.
According to the Chinese expert consensus of ketogenic diet intervention polycystic ovarian syndrome (2018), ketogenic diet is used as a relatively efficient physique management mode, and has relatively wide prospects in clinical application of polycystic ovarian syndrome. However, the ideal is plump, the reality is bone feeling, the ketogenic diet speciality is strong, the daily menu customization has certain complexity, the compliance of patients with three meals a day is poor, the patients easily eat wrong foods without paying attention, and the organism is difficult to achieve the real ketogenic requirement. Therefore, the successful implementation and completion of the ketogenic diet program requires 1 to 1 personalized diet formulation by professional dieticians (high fat, low carbohydrate and appropriate amount of protein are the core of ketogenic diet, so as to formulate the diet of three meals a day). The method has the advantages that the specialty is strong, the time and the labor are consumed, the good compliance of the testee can be ensured only if the method has detailed diet guidance and follow-up capability in hospitals, weight management centers and the like and is equipped with medical institutions of nutrition professionals, otherwise, the dropping rate is high, the withdrawal rate is high, the completion rate is low, and the ketogenic diet treatment course in the true sense is difficult to enter. PCOS patients are a relatively large group in China and tend to rise year by year, but nutrition professionals have large gaps, and implementing ketogenic diet in the group has certain limitation and is not easy to popularize.
Therefore, the full-nutrition meal replacement powder based on the ketogenic principle is urgently needed to be designed according to the physiological and pathological characteristics of the PCOS patients, the compliance and the effectiveness of the drinking intervention of the patients are improved, and the ketogenic diet can be implemented and popularized in larger crowds. By diet management and normal ketogenesis in the population, the aims of successfully losing weight, reducing insulin resistance and intervening PCOS are achieved, and new hopes are brought to patients. The invention relates to a low-GI total nutrient meal replacement powder for intervening polycystic ovarian syndrome based on a ketogenesis principle and application thereof, which are not reported at present.
Disclosure of Invention
The invention aims to provide a low-GI total nutrient meal replacement powder for intervening polycystic ovarian syndrome based on a ketogenic principle and application thereof, aiming at the defects of the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention simulates ketogenic diet, and the body is switched into a functional mode mainly based on fat decomposition in the ketogenic state. The liver condenses acetyl coenzyme A generated by the oxidation of fatty acid B into acetoacetic acid pairwise to synthesize ketone body, and the ketone body is released into blood to be used by extrahepatic tissues, thereby achieving the effect of reducing fat. Provides a convenient alternative diet for PCOS patients. The formula has the advantages that: the formula is scientific, the nutrition is comprehensive, the components cover three macronutrients of carbohydrate, fat and protein, and simultaneously all vitamins and minerals recommended by RNI (2016 (national food guide) edition) of Chinese resident dietary guidelines are provided, and the characteristic that MCT (medium chain triglyceride) cannot become storage fat and can rapidly supply energy to human bodies is utilized, so that the energy intake and storage are controlled, and the purpose of losing weight is achieved.
The energy supply ratio of the ketogenic diet to the three nutrients is as follows: fat 70-75%, carbohydrate 3-5%, protein 20-27%. The energy supply ratio herein means not the weight ratio but the ratio of energy supply. 1 gram of fat can provide 9 kcal of energy. 1 gram of carbohydrate can provide 4 kcal of energy. 1 gram of protein can provide 4 kcal of energy.
Assuming a woman on a strictly ketogenic diet ingests 1200 kcal per day, she would eat approximately 100 grams fat, 60 grams protein and 15 grams carbohydrate per day.
The intervention PCOS meal replacement powder provided by the invention comprises the following components in percentage by weight:
500-2000 parts of raw coconut oil, 100-800 parts of conjugated linoleic acid glyceride, 500-1000 parts of linseed oil, 500-1000 parts of olive oil, 100-500 parts of fish oil, 500-1000 parts of high oleic acid sunflower oil, 500-1000 parts of soybean oil, 1000-2000 parts of concentrated whey protein, 500-1000 parts of soybean protein isolate, 100-500 parts of hydrolyzed fish collagen, 100-500 parts of casein, 100-500 parts of rice protein, 50-200 parts of quinoa flour, 100-200 parts of chia seed, 100-300 parts of konjac fine powder, 100-200 parts of inulin, 100-200 parts of fructo-oligosaccharide, 10-300 parts of L-carnitine, 100-300 parts of glutamine, 100-300 parts of enzyme, 30-70 parts of compound vitamin and 200-300 parts of compound mineral substance.
The compound vitamin is prepared from any two or more of the following raw materials in parts by weight: 1-5 parts of vitamin A, 11-5 parts of vitamin B, 21-5 parts of vitamin B, 61-5 parts of vitamin B, 10-50 parts of vitamin C, 31-5 parts of vitamin D, 5-10 parts of vitamin E, 5-20 parts of nicotinic acid and 5-10 parts of pantothenic acid;
the compound mineral is prepared from any two or more of the following raw materials in parts by weight: 40-50 parts of EDTA (ethylene diamine tetraacetic acid) iron sodium, 10-50 parts of zinc gluconate, 40-50 parts of calcium lactate, 50-100 parts of calcium hydrophosphate, 30-50 parts of magnesium chloride and 50-200 parts of chromium-rich yeast.
Description of the efficacy of the main ingredients:
seed-in-fruit coconut oil:
1. the medium chain fatty acids (MCT) of coconut oil can account for more than 50% of the total fatty acids. MCT has a unique digestive absorption mechanism, in addition to being physically and chemically different from Long Chain Triglycerides (LCTs). MCT can be completely absorbed on the villus of small intestinal mucosa cells or enter the cells without bile salt, the absorption is faster than that of common long-chain fatty acid triglyceride, the generated medium-chain fatty acid does not need to be esterified again in intestinal tract cells to synthesize triglyceride, and directly enters the liver from the portal vein in the form of fatty acid without passing through a shuttle, and the fatty acid is quickly and efficiently decomposed in the liver to generate energy. MCT does not become storage fat and can supply energy to human body quickly.
2. MCT has the advantage of being rapidly digested and absorbed without the need for hydrolysis by pancreatic lipase and absorption without the involvement of the lymphatic system. MCT is metabolized in the liver so that it does not become fat storage but only energy production, so energy intake and storage can be controlled by ingesting MCT instead of part of conventional fat for the purpose of weight control.
Seed oil is formed:
1. the linseed oil has complete amino acid types, the essential amino acid content is as high as 5.16 percent, and the nutritional value is very high.
2. The linseed oil contains 53% of alpha-linolenic acid, which is an essential fatty acid for human body and can be converted into eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in human body.
3. The alpha-linolenic acid has the functions of resisting tumor, resisting thrombus, reducing blood fat, nourishing brain cell, regulating vegetative nerve, etc.
: (i) conjugated linoleic acid glyceride:
1. weight loss: can inhibit fat deposition, increase the oxidative decomposition of fatty acids in fat cells, and reduce the volume of fat cells.
2. The tumor inhibition effect is as follows: inhibiting skin cancer, gastric cancer, breast cancer and intestinal cancer.
3. And (3) enhancing immunity: the Conjugated Linoleic Acid (CLA) is extracted from safflower, is a series of double-bond linoleic acids, has the functions of eliminating free radicals, enhancing the oxidation resistance and the immunity of a human body, promoting growth and development, regulating blood cholesterol, preventing atherosclerosis, promoting fat oxidative decomposition, promoting the synthesis of protein of the human body and carrying out comprehensive benign regulation on the human body.
4. And (3) reducing blood fat: CLA can play a role of 'vascular scavenger', can remove garbage in blood vessels, effectively regulate blood viscosity, and achieve the effects of relaxing blood vessels, improving microcirculation and stabilizing blood pressure. In particular, the reduction of diastolic blood pressure is more pronounced.
5. Promoting bone development and growth: enhance the synthesis of cartilage cells in ossein and accelerate the synthesis of bones.
Fructus Canarii albi oil
Contains a large amount of monounsaturated fatty acid and abundant fat-soluble vitamins such as vitamin A, D, E, K.
1. Protecting the cardiovascular system: can increase the level of high density lipoprotein HDL and reduce the level of low density lipoprotein LDL in human body, thereby preventing cholesterol excess in human body.
2. Improving the function of an endocrine system: can increase insulin sensitivity.
3. Improving the function of the digestive system: can stimulate bile secretion, activate pancreatin activity, degrade oil, and be absorbed by intestinal mucosa to reduce cholecystitis and cholelithiasis.
Fish oil
Is rich in omega-3 polyunsaturated fatty acids (DHA and EPA), and has effects of lowering blood sugar, regulating blood lipid, and reducing cholesterol. EPA has effects in reducing cholesterol and triglyceride, and promoting saturated fatty acid metabolism. Thereby reducing blood viscosity, promoting blood circulation, and improving oxygen supply to tissue to relieve fatigue. Preventing fat deposition on blood vessel wall, preventing atherosclerosis formation and development, and preventing cardiovascular diseases such as cerebral thrombosis, cerebral hemorrhage, hypertension, etc.
High oleic acid sunflower seed oil
1. Is rich in linoleic acid, which is essential fatty acid, and has effects of regulating metabolism, maintaining blood pressure balance, and reducing cholesterol in blood.
2 contains abundant vitamin E, and has effects of delaying human body cell aging and maintaining youth.
3. Contains nutrient substances such as phytosterol and phospholipid, and can prevent serum cholesterol from increasing.
Seed oil of soybean
Contains abundant linoleic acid, which is essential fatty acid for human body, and has effects of regulating metabolism, maintaining blood pressure balance, and reducing cholesterol in blood.
::
1. the whey protein is the most excellent and ideal protein supplement, the amino acid proportion is optimal, and the utilization rate is 1.7 times of that of the soybean protein.
2. Contains rich alpha-lactalbumin and beta-lactoglobulin active components, is easier to digest and absorb, and has the highest biological value.
3. Is rich in cysteine, immunoglobulin and methionine, and has effects of improving immunity and strengthening body constitution.
4. Whey protein prevents the development of chemically induced cancer.
5. Increase skeletal strength and decrease LDL cholesterol levels.
Protein isolate from soybean:
1. the isolated soy protein has a protein content of above 90%, and approximately 20 kinds of amino acids, and contains essential amino acids for human body. It is nutritious, free of cholesterol, and can substitute for animal protein.
2. The soybean protein is relatively lack of methionine, the whey protein is rich in methionine, the combination of the two, and the combination of the whey protein and the soybean protein can obviously improve the nutritional value of the protein powder. The protein content is as high as 80-85%, the rapid absorption rate is 96%, and the protein is more easily absorbed by human body. At the same time, 9 kinds of amino acids essential for human body can be provided.
Rice protein:
the rice protein has reasonable amino acid composition balance and high amino acid content, conforms to an ideal mode recommended by WHO/FAO, and can reduce the content of serum cholesterol and reduce the damage of atherosclerosis to arteries.
: (i) inulin:
1. controlling blood fat.
2. Lower blood glucose (not hydrolyzed to monosaccharides in the upper part of the intestinal tract and thus not raise blood glucose levels and insulin content).
3. Promoting mineral absorption.
4. Regulating intestinal microbial flora, improving intestinal health, and preventing constipation.
5. Inhibiting the generation of toxic fermentation product, protecting liver, and preventing colon cancer.
6. Preventing and treating constipation and obesity (action of dietary fiber)
Chenopodium quinoa powder
1. Quinoa is a whole-grain, full-nutrient, complete-protein alkaline food, and is a Chenopodiaceae plant, the protein content of which is equivalent to that of beef, and the quality of which is not inferior to that of meat-derived protein and milk-derived protein. Chenopodium quinoa contains abundant amino acids, 9 essential amino acids necessary for human beings, and also contains many non-essential amino acids, especially lysine which most crops do not have, and contains abundant and high-content mineral elements, and various vitamins which are needed by normal metabolism of human bodies, and does not contain cholesterol and gluten, and the sugar content, fat content and calorie are all low levels.
2. The quinoa is rich in vitamins, polyphenols, flavonoids, saponins and phytosterols, and has various health effects.
3. Quinoa has high protein, contains unsaturated fatty acid 83% in fat, is a low fructose and low glucose food, and can exert beneficial effect in glycolipid metabolism.
: (Amorphophallus rivieri) powder
1. The medicinal components of rhizoma Amorphophalli can remove fat and cholesterol deposited in cardiovascular system. The konjak contains rich dietary fiber, and the dietary fiber in the intestinal tract can strengthen the intestinal tract peristalsis, promote defecation and shorten the retention time of food in the intestinal tract. The konjac glucomannan has high viscosity, enhances the viscosity of chyme in the digestive tract, delays the detention time of chyme paste in the gastric cavity, forms a protective film on the intestinal wall, and effectively inhibits the increase of blood sugar value and urine sugar value.
2. The Haimanna substance in the konjak can make people feel full after eating, thereby reducing the quantity of food taken by people and energy consumption of fat in the human body, and being beneficial to controlling the weight of people.
:fructooligosaccharide:
1. fructooligosaccharide is an activated proliferation factor of intestinal Bacillus bifidus, and can reduce and inhibit the generation of intestinal putrefactive substances, inhibit the growth of harmful bacteria, and regulate intestinal homeostasis.
2. Can promote the absorption and utilization of trace elements of iron and calcium to prevent osteoporosis.
2. Can reduce liver toxin, can generate anticancer organic acid in intestines, and has obvious cancer prevention function; and the sweet and pure taste, the fat-like fragrance and the smooth and greasy taste are provided, and the sweet and pure taste is an ideal sweetener in health food.
Glutamine-
1. And the intestinal mucosa barrier function is maintained.
2. Promote the immune cell replication and maintain the immune cell function.
3. Reducing muscle breakdown, improving nitrogen balance, and promoting protein synthesis.
4. Promoting glutathione synthesis, reducing oxygen free radical, and relieving inflammation.
Population adaptation and inclusion criteria:
according to 2018 Chinese treatment guidelines for polycystic ovarian syndrome, the diagnosis standard of polycystic ovarian syndrome is infrequent menstruation, amenorrhea or irregular vaginal bleeding, and the ketogenic nutrition powder can be involved if the diagnosis standard further meets 1 of the following 2 items:
(ii) hyperandrogenism clinical presentation or hyperandrogenism;
(II) ultrasound images show ovarian polycystic appearance and exclude other diseases causing hyperandrogenism and anovulation abnormality. Meanwhile, the BMI is more than or equal to 24kg/m2Or the body fat rate is more than or equal to 28 percent.
Contraindications:
metabolic taboo: the ketogenic diet is a therapy with fat instead of glucose as an energy source, so all diseases with fatty acid transport and oxidation disorder cannot be treated.
(II) contraindication of complications: urinary calculus, renal failure history or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, pancreatitis history, severe diabetes, active gallbladder disease, lipodystrophy, severe cardiovascular and cerebrovascular diseases, etc.
(III) oral medication contraindication: antiepileptic drugs such as zonisamide, tolbutamide and acetazolamide can cause acidosis, which is exacerbated when treated with ketogenic diets.
(IV) special situation contraindications: pregnant, lactating, infecting, eating difficulties, uncooperative patients.
Adverse reactions and countermeasures:
(one) hypoglycemia: by using a 'flexible ketogenesis' mode, the intake of carbohydrates is gradually reduced in 1-2 weeks, so that the occurrence of hypoglycemia reaction can be obviously reduced. When the blood sugar is more than or equal to 2.2mmol/L, if no symptom exists, the treatment can be stopped; if the concentration is less than 2.2mmol/L, the oral administration of orange juice or glucose can be used for symptomatic treatment.
(II) weakness, dizziness and fatigue: the feelings of fatigue, dizziness, fatigue or tremor may be due to dehydration of the body and/or loss of minerals, and mineral supplementation with water and green leaf vegetables may be significantly improved.
(III) constipation: constipation may be associated with inadequate dietary fiber intake, as well as magnesium deficiency and dehydration. Can be solved by using medicines for promoting intestinal peristalsis, magnesium supplement, dietary fiber supplement and the like.
(tetra) ketosis overabundance: can be used for oral administration of a small amount of carbohydrate, carbon dioxide binding force examination or blood gas analysis; if the acidosis is more than moderate, the carbohydrate ratio of ketogenic diet can be properly increased, and the symptomatic treatment is carried out.
(V) vitamin and mineral deficiencies: the diuretic action of ketone bodies and the diet control, which often accompany patients with vitamin and mineral deficiencies, strongly advise the supplementation of water-soluble vitamin and mineral preparations.
(VI) lethargy or poor spirit: the treatment time is usually short, and symptoms disappear after 1-2 weeks, and the treatment can be carried out according to symptoms. Detecting ketone bodies, blood sugar, etc.
(VII) diarrhea or abdominal pain: mainly due to intestinal spasm caused by medium-chain fatty acid, the anisodamine tablet can be orally taken to relieve.
Instructions and prompts for use:
the patient is advised to start the ketogenic diet by adopting a 'flexible ketogenic' mode, and the fat energy supply ratio is gradually increased in 1-2 weeks. The treatment period and scheme are determined according to the weight loss condition, endocrine metabolism and other index improvement conditions, and the blood sugar, blood fat, blood ketone, hormone level and the like are continuously monitored in the period. When BMI<24kg/m2The ketogenic diet intervention can be stopped, the ketogenic process is carried out about 2 weeks before the stopping, the balanced diet is gradually returned, the long-term diet management is carried out, the PCOS related endocrine indexes are periodically reviewed, the body mass is maintained at a normal level, and the probability of recurrent diseases and obesity is reduced.
The invention has the advantages that:
the components in the formula have synergistic effect, and simultaneously have the characteristics of controlling blood sugar, relieving Insulin Resistance (IR), improving glycolipid metabolic disturbance and regulating endocrine. The health food is suitable for life style intervention and diet regulation of patients with Polycystic Ovary Syndrome (PCOS), and is a healthy and convenient meal replacement for people who are on diet intervention plan and busy and green on the premise of meeting all vitamins and minerals of daily necessary calorie and dietary guideline RNI.
Detailed Description
The invention will be further illustrated with reference to specific embodiments. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Furthermore, it should be understood that various changes and modifications can be made by those skilled in the art after reading the disclosure of the present invention, and equivalents fall within the scope of the appended claims.
Example 1 meal replacement powder
Calculating the meal powder with the cost of 100 KG:
15kg of raw coconut oil, 5kg of conjugated linoleic acid glyceride, 8kg of linseed oil, 8kg of olive oil, 5kg of fish oil, 5kg of high-oleic acid sunflower seed oil, 5kg of soybean oil, 15kg of concentrated whey protein, 8kg of soybean protein isolate, 2kg of hydrolyzed fish collagen, 5kg of casein, 5kg of rice protein, 2kg of quinoa powder, 1kg of chia seed, 3kg of konjac fine powder, 1kg of inulin, 1kg of fructo-oligosaccharide, 0.5kg of L-carnitine, 1.5kg of glutamine, 1.5kg of ferment, 0.3kg of compound vitamin and 2kg of compound mineral matter are weighed according to the formula, then respectively sieved by an 80-mesh sieve, and the un-sieved part is crushed and sieved again until the whole is sieved. Packaging each bag with 20g of finished product.
EXAMPLE 2 clinical trials
According to two national standards of general guidelines of formula food for special medical applications (GB29922-2013) and good production specifications of formula food for special medical applications (GB29923-2013) published by the State Ministry of health Commission in 2013, effect evaluation clinical tests are performed on the meal replacement powder prepared in example 1.
Preliminary experimental results and effect evaluation at the early stage:
the tested PCOS patients are subjected to the discovery of the ketogenic meal replacement powder diet intervention in the period of 8 weeks, and relevant indexes change before and after the intervention:
the mass (-8.61 +/-2.34) kg, P is less than 0.001;
body Mass Index (BMI) (-3.25. + -. 0.88) kg/m2，P＜0.001；
Waist circumference (-8.4 + -3.1) cm, P is less than 0.001;
fasting insulin (-17.0 +/-13.6) microgram/mL, P is less than 0.001;
2h insulin (-82.8 +/-177.7) mu g/mL, wherein P is less than 0.05;
total testosterone levels (-10.0 + -17.0) ng/dL, P < 0.001;
free testosterone levels of-1.8 pg/dL, P < 0.05;
the LH/FSH is reduced by 36 percent, and P is less than 0.05;
the research preliminarily proves that the ketogenic meal replacement powder can not only obviously improve the body mass and the insulin resistance of a PCOS patient, but also has obvious effect on hyperandrogenism complicated by the PCOS. The endocrine disorder of the patient is remarkably improved.
Example 3 animal experiments
1 materials and methods
1.1 animal model construction and drug delivery
Selecting 70-day-old healthy and clean female Spragudarey (SD) rats, establishing a polycystic ovary syndrome (PCOS) rat model according to a Poretsky method, subcutaneously injecting chorionic gonadotropin (HCG)3.0U/d 2 times a day, gradually increasing the effective insulin from 0.5U/d to 6.0U/d from the injection on the 1 st to the 10 th days, injecting the effective insulin at the dose every day, and detecting that the level of testosterone and insulin in the rat is increased and the vaginal smear continuously generates keratinocytes to accord with the PCOS model after 22 days.
After the model building is successful, the model rats are divided into four groups, namely an experimental group, a comparative two groups and a control group.
Wherein, the experimental group drenches the following medicines (according to the formula of the ketogenic of the patent, the energy supply ratio of the three nutrients is 70-75% of fat, 3-5% of carbohydrate and 20-27% of protein): experimental groups: raw materials: the composition is characterized by comprising the following raw materials in parts by weight: 2000 parts of raw coconut oil, 800 parts of conjugated linoleic acid glyceride, 1000 parts of linseed oil, 1000 parts of olive oil, 500 parts of fish oil, 1000 parts of high-oleic sunflower oil, 1000 parts of soybean oil, 2000 parts of concentrated whey protein, 1000 parts of soybean protein isolate, 500 parts of hydrolyzed fish collagen, 500 parts of casein, 500 parts of rice protein, 200 parts of quinoa wheat flour, 200 parts of chia seed, 300 parts of konjac refined powder, 200 parts of inulin, 200 parts of fructo-oligosaccharide, 300 parts of L-carnitine, 300 parts of glutamine, 300 parts of enzyme, 5 parts of vitamin A, 5 parts of vitamin B15 portions of vitamin B25 portions of vitamin B65 parts of vitamin C, 50 parts of vitamin D35 parts of vitamin E10 parts, 20 parts of nicotinic acid, 0 part of pantothenic acid, 50 parts of EDTA (ethylene diamine tetraacetic acid) iron sodium, 50 parts of zinc gluconate, 50 parts of calcium lactate, 100 parts of calcium hydrophosphate, 50 parts of magnesium chloride and 200 parts of chromium-enriched yeast. Pulverizing the above materials and making into powder.
The formula of the gastric lavage medicine of the comparative example group is the same as that of the experimental group, and the difference is that the weight parts of the components are differentThe same: comparative example one set: raw materials: the composition is characterized by comprising the following raw materials in parts by weight: 2200 parts of raw coconut oil, 900 parts of conjugated linoleic acid glyceride, 1100 parts of linseed oil, 1100 parts of olive oil, 600 parts of fish oil, 1100 parts of high-oleic sunflower seed oil, 1100 parts of soybean oil, 2200 parts of concentrated whey protein, 1100 parts of soybean protein isolate, 600 parts of hydrolyzed fish collagen, 600 parts of casein, 600 parts of rice protein, 300 parts of quinoa wheat flour, 300 parts of chia seed, 400 parts of konjac refined powder, 300 parts of inulin, 300 parts of fructo-oligosaccharide, 400 parts of L-carnitine, 400 parts of glutamine, 400 parts of enzyme, 5 parts of vitamin A, 5 parts of vitamin B15 portions of vitamin B25 portions of vitamin B65 parts of vitamin C, 50 parts of vitamin D35 parts of vitamin E10 parts, 20 parts of nicotinic acid, 0 part of pantothenic acid, 50 parts of EDTA (ethylene diamine tetraacetic acid) iron sodium, 50 parts of zinc gluconate, 50 parts of calcium lactate, 100 parts of calcium hydrophosphate, 50 parts of magnesium chloride and 200 parts of chromium-enriched yeast. Pulverizing the above materials and making into powder.
Comparative examples two groups: the difference between the intragastric administration medicine and the experimental group lies in that the composition of the medicine is different, the medicine is a balanced type total nutrient formula, the balanced diet mode of the dietary guideline is met, and the energy supply ratio of three nutrients is as follows: carbohydrate 60%, protein 25%, fat 15%): comparative examples two groups: raw materials: the composition is characterized by comprising the following raw materials in parts by weight: 1600 parts of hydrolyzed corn starch, 200 parts of maltodextrin, 100 parts of inulin, 100 parts of fructo-oligosaccharide, 100 parts of sunflower seed oil, 100 parts of soybean oil, 400 parts of casein powder, 400 parts of isolated whey protein, 0.1 part of potassium citrate, 0.1 part of sodium citrate, 10 parts of tricalcium phosphate, 0.1 part of magnesium chloride, 10 parts of potassium chloride, 0.1 part of phospholipid, 10 parts of L-ascorbic acid, 0.1 part of ferric pyrophosphate, 0.1 part of zinc sulfate, 10 parts of nicotinamide, 10 parts of tocopherol, 0.1 part of manganese sulfate, 0.1 part of thiamine hydrochloride, 0.1 part of pyridoxine hydrochloride, 0.1 part of riboflavin, 0.1 part of folic acid, 10 parts of beta-carotene, 0.1 part of chromium chloride, 0.1 part of D-biotin and 10 parts of vitamin D.
Control group: daily gavage of the same dosage of oral glucose solution can maintain daily energy supply and fluid balance).
Each group was injected once a week, the dose was converted according to the conventional conversion method of the dose administered to human, and the rats in each group were sacrificed by bleeding after 6 weeks.
1.2 specimen Collection and measurement
Observation of ovarian tissue morphology:
after the rat is broken and blood is taken, immediately laparotomy is carried out to take out bilateral ovaries of the rat, liquid is wiped dry, the weight of the ovaries is measured by a precision electronic balance, the weight of the ovaries is recorded, the ovarian index is calculated, the ovarian index is equal to the wet weight (mg) of the ovaries/the weight (g) multiplied by 100%, a specimen is fixed in 10% formaldehyde solution for 48 hours, the ovary index is placed in an automatic dehydrator and is dehydrated and soaked in wax, the conventional paraffin is embedded at 70 ℃, the ovary index is placed in a refrigerator to be frozen for 20 minutes and then is sliced, the slice thickness is 4 mu m, HE staining is carried out, and. The number of follicles at each stage and the ovarian morphology were observed under an optical microscope.
1.3 statistical methods:
all the metered data are expressed as mean ± standard deviation and statistically analyzed using SPSS16.0 statistical software. P <0.05 represents that the difference is significant and has statistical significance.
2 results
And (3) comparing the ovary indexes: rat ovarian weights were converted to ovarian index (ovarian weight as a percentage of body weight). The result shows that the ovary index of the rat in the experimental group is obviously lower than that of other groups, and the comparison difference is statistically different, which shows that the medicine provided by the experimental group can reduce the ovary index of the POS rat model to a certain extent.
Morphological changes of ovaries: the ovary of the experimental group can see all levels of follicles and a plurality of corpus luteum, cystic follicle dilatation follicles are rarely seen, the cumulus oophorus and follicular fluid can be seen in the dominant follicle, and the number of granulosa cells is obviously increased. The ovary volume of other groups is increased, the luteal formation is obviously less than that of the experimental group, the cystic expansion of the follicle is obviously more than that of the experimental group, the basic structures such as oocyte and radial corona are not seen, and only 1-2 layers of granular cells and a large number of atretic follicles are seen. The formula of the invention is proved to have application value in the aspect of preparing and treating polycystic ovarian syndrome.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and additions can be made without departing from the principle of the present invention, and these should also be considered as the protection scope of the present invention.

Claims (9)

1. The low-GI total nutrient meal replacement powder for intervening in polycystic ovarian syndrome based on the ketogenesis principle is characterized in that the energy supply ratio of each nutrient in the meal replacement powder is as follows: fat 70-75%, carbohydrate 3-5%, protein 20-27%; the meal replacement powder is prepared from the following raw materials in parts by weight: 500-2000 parts of raw coconut oil, 100-800 parts of conjugated linoleic acid glyceride, 500-1000 parts of linseed oil, 500-1000 parts of olive oil, 100-500 parts of fish oil, 500-1000 parts of high oleic acid sunflower oil, 500-1000 parts of soybean oil, 1000-2000 parts of concentrated whey protein, 500-1000 parts of soybean protein isolate, 100-500 parts of hydrolyzed fish collagen, 100-500 parts of casein, 100-500 parts of rice protein, 50-200 parts of quinoa flour, 100-200 parts of chia seed, 100-300 parts of konjac fine powder, 100-200 parts of inulin, 100-200 parts of fructo-oligosaccharide, 10-300 parts of L-carnitine, 100-300 parts of glutamine, 100-300 parts of enzyme, 30-70 parts of compound vitamin and 200-300 parts of compound mineral substance;
the compound vitamin is prepared from any two or more of the following raw materials in parts by weight: 1-5 parts of vitamin A, 11-5 parts of vitamin B, 21-5 parts of vitamin B, 61-5 parts of vitamin B, 10-50 parts of vitamin C, 31-5 parts of vitamin D, 5-10 parts of vitamin E, 5-20 parts of nicotinic acid and 5-10 parts of pantothenic acid;
the compound mineral is prepared from any two or more of the following raw materials in parts by weight: 40-50 parts of EDTA (ethylene diamine tetraacetic acid) iron sodium, 10-50 parts of zinc gluconate, 40-50 parts of calcium lactate, 50-100 parts of calcium hydrophosphate, 30-50 parts of magnesium chloride and 50-200 parts of chromium-rich yeast.
2. The meal replacement powder according to claim 1, wherein the meal replacement powder is prepared from the following raw materials in parts by weight: 1000-1500 parts of raw coconut oil, 300-600 parts of conjugated linoleic acid glyceride, 700-800 parts of linseed oil, 700-800 parts of olive oil, 200-500 parts of fish oil, 500-800 parts of high oleic acid sunflower oil, 500-800 parts of soybean oil, 1500-1800 parts of concentrated whey protein, 500-800 parts of soybean protein isolate, 200-400 parts of hydrolyzed fish collagen, 200-500 parts of casein, 200-500 parts of rice protein, 100-200 parts of quinoa flour, 100-150 parts of chia seed, 200-300 parts of konjac fine powder, 100-150 parts of inulin, 100-150 parts of fructo-oligosaccharide, 50-200 parts of L-carnitine, 150-200 parts of glutamine, 150-200 parts of enzyme, 30-70 parts of compound vitamin and 200-300 parts of compound mineral substance;
the compound vitamin is prepared from any two or more of the following raw materials in parts by weight: 1-5 parts of vitamin A, 11-5 parts of vitamin B, 21-5 parts of vitamin B, 61-5 parts of vitamin B, 10-50 parts of vitamin C, 31-5 parts of vitamin D, 5-10 parts of vitamin E, 5-20 parts of nicotinic acid and 5-10 parts of pantothenic acid;
the compound mineral is prepared from any two or more of the following raw materials in parts by weight: 40-50 parts of EDTA (ethylene diamine tetraacetic acid) iron sodium, 10-50 parts of zinc gluconate, 40-50 parts of calcium lactate, 50-100 parts of calcium hydrophosphate, 30-50 parts of magnesium chloride and 50-200 parts of chromium-rich yeast.
3. The meal replacement powder according to claim 1, wherein the meal replacement powder is prepared from the following raw materials in parts by weight: 1500 parts of raw coconut oil, 600 parts of conjugated linoleic acid glyceride, 800 parts of linseed oil, 800 parts of olive oil, 500 parts of fish oil, 800 parts of high-oleic acid sunflower seed oil, 800 parts of soybean oil, 1800 parts of concentrated whey protein, 800 parts of soybean protein isolate, 400 parts of hydrolyzed fish collagen, 500 parts of casein, 500 parts of rice protein, 200 parts of quinoa wheat flour, 150 parts of chia seed, 300 parts of konjac refined powder, 150 parts of inulin, 150 parts of fructo-oligosaccharide, 200 parts of L-carnitine, 200 parts of glutamine, 200 parts of enzyme, 70 parts of compound vitamin and 300 parts of compound mineral substance;
the compound vitamin is prepared from any two or more of the following raw materials in parts by weight: 1-5 parts of vitamin A, 11-5 parts of vitamin B, 21-5 parts of vitamin B, 61-5 parts of vitamin B, 10-50 parts of vitamin C, 31-5 parts of vitamin D, 5-10 parts of vitamin E, 5-20 parts of nicotinic acid and 5-10 parts of pantothenic acid;
the compound mineral is prepared from any two or more of the following raw materials in parts by weight: 40-50 parts of EDTA (ethylene diamine tetraacetic acid) iron sodium, 10-50 parts of zinc gluconate, 40-50 parts of calcium lactate, 50-100 parts of calcium hydrophosphate, 30-50 parts of magnesium chloride and 50-200 parts of chromium-rich yeast.
4. The meal replacement powder of claim 1, wherein the raw materials are prepared into powder which is easy to take and absorb according to a conventional pharmaceutical preparation method.
5. The meal replacement powder of claim 1, wherein the preparation method comprises: and (3) crushing the raw materials according to the weight parts, sieving the crushed raw materials by a 80-mesh sieve, and packaging the sieved raw materials into a finished product.
6. Use of the meal replacement powder of claim 1 for the manufacture of a medicament for controlling blood glucose, alleviating insulin resistance, ameliorating glycolipid metabolic disorders, and regulating endocrine.
7. Use of a meal replacement powder according to claim 1 for the manufacture of a medicament for the treatment of infertility and/or miscarriage.
8. Use of the meal replacement powder of claim 1 in the manufacture of a medicament for the treatment of polycystic ovary syndrome.
9. The use according to claim 8, wherein the polycystic ovary syndrome is associated with any one or both of the following symptoms: (ii) hyperandrogenism clinical presentation or hyperandrogenism; (II) the ultrasonic image shows the ovarian polycystic appearance, and meanwhile, the BMI is more than or equal to 24kg/m2Or the body fat rate is more than or equal to 28 percent.
CN202011254933.5A 2020-11-11 2020-11-11 Low-GI (glycemic index) total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on ketogenesis principle and application of low-GI total-nutrient meal replacement powder Pending CN112352955A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011254933.5A CN112352955A (en) 2020-11-11 2020-11-11 Low-GI (glycemic index) total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on ketogenesis principle and application of low-GI total-nutrient meal replacement powder

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011254933.5A CN112352955A (en) 2020-11-11 2020-11-11 Low-GI (glycemic index) total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on ketogenesis principle and application of low-GI total-nutrient meal replacement powder

Publications (1)

Publication Number Publication Date
CN112352955A true CN112352955A (en) 2021-02-12

Family

ID=74516004

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011254933.5A Pending CN112352955A (en) 2020-11-11 2020-11-11 Low-GI (glycemic index) total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on ketogenesis principle and application of low-GI total-nutrient meal replacement powder

Country Status (1)

Country Link
CN (1) CN112352955A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109221909A (en) * 2018-10-22 2019-01-18 四川环太生物科技股份有限公司 A kind of no seitan functional food and preparation method thereof
CN114424826A (en) * 2022-04-06 2022-05-03 北京群峰纳源健康科技有限公司 Application of intestinal flora characteristic bacteria in dietary nutrition intervention of PCOS patients

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102648749A (en) * 2012-04-24 2012-08-29 广州金酮医疗科技有限公司 Ketogenic nutritional powder
CN102919676A (en) * 2012-11-14 2013-02-13 内蒙古三主粮谷物科技股份有限公司 Hulless oat bran nutrition powder for losing weight and preparation method thereof
CN107343657A (en) * 2017-06-05 2017-11-14 深圳市捷利康生物科技有限公司 High fat diet formula powder
CN107960664A (en) * 2017-12-01 2018-04-27 春雨壹品（北京）国际信息科技有限公司 A kind of nutrition fat-reduced food
CN110810845A (en) * 2019-12-03 2020-02-21 复旦大学附属金山医院 Total nutrient formula powder with ketogenesis, fat reduction and sugar resistance functions and application thereof
CN111084381A (en) * 2019-12-18 2020-05-01 东莞自然衡健康科技有限公司 Ketogenic nutritional meal replacement powder and application

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102648749A (en) * 2012-04-24 2012-08-29 广州金酮医疗科技有限公司 Ketogenic nutritional powder
CN102919676A (en) * 2012-11-14 2013-02-13 内蒙古三主粮谷物科技股份有限公司 Hulless oat bran nutrition powder for losing weight and preparation method thereof
CN107343657A (en) * 2017-06-05 2017-11-14 深圳市捷利康生物科技有限公司 High fat diet formula powder
CN107960664A (en) * 2017-12-01 2018-04-27 春雨壹品（北京）国际信息科技有限公司 A kind of nutrition fat-reduced food
CN110810845A (en) * 2019-12-03 2020-02-21 复旦大学附属金山医院 Total nutrient formula powder with ketogenesis, fat reduction and sugar resistance functions and application thereof
CN111084381A (en) * 2019-12-18 2020-05-01 东莞自然衡健康科技有限公司 Ketogenic nutritional meal replacement powder and application

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
孙桂菊，等: "《护理营养学》", 东南大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109221909A (en) * 2018-10-22 2019-01-18 四川环太生物科技股份有限公司 A kind of no seitan functional food and preparation method thereof
CN114424826A (en) * 2022-04-06 2022-05-03 北京群峰纳源健康科技有限公司 Application of intestinal flora characteristic bacteria in dietary nutrition intervention of PCOS patients

Similar Documents

Publication Publication Date Title
US6468962B1 (en) Nutritional intervention composition for enhancing and extending satiety
US20020187204A1 (en) Diet composition and method of weight management
US8962689B2 (en) Medium chain dicarboxylic acids, their derivates and metabolic disorders
CN106072573A (en) A kind of it is applicable to the special dietary seafood that old aged muscle decay disease is edible
CN103238897A (en) Composite plant solid drink suitable for diabetic patients
CN110810845A (en) Total nutrient formula powder with ketogenesis, fat reduction and sugar resistance functions and application thereof
CN101744170A (en) Tartary buckwheat eight ingredient porridge suitable for patients with diabetes and preparing method thereof
CN110226744A (en) A kind of prostatitis tailored version clinical nutrition formula and preparation method thereof
CN105815514A (en) Weight-losing quinoa milk tea
CN109745359A (en) Be conducive to keep blood glucose balance and prevent diabetes and its composition of complication and preparation method thereof
CN112352955A (en) Low-GI (glycemic index) total-nutrient meal replacement powder for intervening polycystic ovarian syndrome based on ketogenesis principle and application of low-GI total-nutrient meal replacement powder
CN110101088A (en) Accurate nutritional meal replacement composition and its application method for gestational diabetes mellitus prevention and treatment
CN113826799A (en) Diet food
CN102499291B (en) Milk powder with functions of maintaining beauty and keeping young and improving immunity of organism and preparation method thereof
CN111543605A (en) Comprehensive nutrition powder for people with hypertension, hyperlipidemia and obesity
CN114711374A (en) Composite nutrient powder of ferment fibre and its preparation method
CN105410930A (en) Health-care product with weight-losing and body-slimming and nutrition-balancing functions and preparation method thereof
CN108541912A (en) A kind of anti-oxidant blood-fat reducing composition and its preparation method and application
US20060135444A1 (en) Combination of flavonoid and procyanidin for the reduction of the mammalian appetite
CN109303115A (en) Raw ketone weight losing meal-replacing milk shake
US7416750B1 (en) Composition to provide maintenance and nutritional support in glycemic control deficits
CN106035686A (en) Super chenopodium quinoa willd health-preservation plant milk
CN103330118A (en) Antiobesity drug
CN112690386A (en) A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity
Giampapa Every man takes the limits of his own field of vision for the limits of the world.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210212

RJ01 Rejection of invention patent application after publication